OpportunityAnalyzer: B-Cell Non-Hodgkin’s Lymphoma (NHL) – Opportunity Analysis and Forecasts to 2024

Table 1: Non-Hodgkin’s Lymphoma Subtypes

Table 2: Symptoms of Non-Hodgkin’s Lymphoma

Table 3: The Ann Arbor Staging System and the Cotswold Modifications for NHL

Table 4: Molecular Characteristics of Non-Hodgkin’s Lymphoma (2008 WHO Classification)

Table 5: Treatment Guidelines for Non-Hodgkin’s Lymphoma in the 7MM

Table 6: Risk Factors and Comorbidities for NHL

Table 7: US, Age- and Sex-Specific Incidence of B-Cell NHL During 2001–2010

Table 8: 7MM, Sources of B-Cell NHL Incidence Data

Table 9: 7MM, Incident Cases of Follicular Lymphoma, Ages =30 Years, Both Sexes, N, Selected Years 2014–2024

Table 10: 7MM, Age-Specific Incident Cases of Follicular Lymphoma, Both Sexes, N (Row %), 2014

Table 11: 7MM, Sex-Specific Incident Cases of Follicular Lymphoma, Ages =30 Years, N (Row %), 2014

Table 12: 7MM, Incident Cases of Marginal Zone Lymphoma, Ages =30 Years, Both Sexes, N, Selected Years 2014–2024

Table 13: 7MM, Age-Specific Incident Cases of Marginal Zone Lymphoma, Both Sexes, N (Row %), 2014

Table 14: 7MM, Sex-Specific Incident Cases of Marginal Zone Lymphoma, Ages =30 Years, N (Row %), 2014

Table 15: 7MM, Incident Cases of DLBCL, Ages =30 Years, Both Sexes, N, Selected Years, 2014–2024

Table 16: 7MM, Age-Specific Incident Cases of DLBCL, Both Sexes, N (Row %), 2014

Table 17: 7MM, Sex-Specific Incident Cases of DLBCL, Ages =30 Years, N (Row %), 2014

Table 18: 7MM, Incident Cases of Mantle Cell Lymphoma, Ages =30 Years, Both Sexes, N, Selected Years 2014–2024

Table 19: 7MM, Age-Specific Incident Cases of Mantle Cell Lymphoma, Both Sexes, N (Row %), 2014

Table 20: 7MM, Sex-Specific Incident Cases of Mantle Cell Lymphoma, Ages =30 Years, N (Row %), 2014

Table 21: Leading Treatments for NHL Patients in the 7MM

Table 22: Product Profile – Imbruvica

Table 23: Efficacy of Imbruvica in MCL

Table 24: Efficacy of Imbruvica in FL

Table 25: Efficacy of Imbruvica in DLBCL

Table 26: Safety of Imbruvica in MCL

Table 27: Imbruvica SWOT Analysis, 2015

Table 28: Product Profile – Revlimid

Table 29: Efficacy of Revlimid in MCL

Table 30: Efficacy of Revlimid in DLBCL

Table 31: Efficacy of Revlimid in DLBCL

Table 32: Safety of Revlimid

Table 33: Revlimid SWOT Analysis, 2015

Table 34: Product Profile – Rituxan

Table 35: Efficacy of Rituxan

Table 36: Safety of Rituxan

Table 37: Rituxan SWOT Analysis, 2015

Table 38: Product Profile – Treanda

Table 39: Efficacy of Treanda

Table 40: Safety of Treanda

Table 41: Treanda SWOT Analysis, 2015

Table 42: Product Profile – Velcade

Table 43: Efficacy of Velcade

Table 44: Safety of Velcade

Table 45: Velcade SWOT Analysis, 2015

Table 46: Product Profile – Zevalin

Table 47: Efficacy of Zevalin

Table 48: Safety of Zevalin

Table 49: Zevalin SWOT Analysis, 2015

Table 50: Product Profile – Zydelig

Table 51: Efficacy of Zydelig

Table 52: Safety of Zydelig

Table 53: Zydelig SWOT Analysis, 2015

Table 54: Overall Unmet Needs – Current Level of Attainment

Table 55: Key Products in the Present and Future B-Cell NHL Market, 2015

Table 56: Design of Current Registration Trials in Indolent B-Cell NHL

Table 57: Design of Current Registration Trials in Aggressive B-Cell NHL

Table 58: Non-Hodgkin’s Lymphoma – Late-Stage Pipeline, 2015

Table 59: Product Profile – Afinitor

Table 60: Efficacy of Afinitor in DLBCL

Table 61: Safety of Afinitor in DLBCL

Table 62: Afinitor SWOT Analysis, 2015

Table 63: Product Profile – Arzerra

Table 64: Efficacy of Arzerra in FL

Table 65: Safety of Arzerra in FL

Table 66: Arzerra SWOT Analysis, 2015

Table 67: Product Profile – Copanlisib

Table 68: Efficacy of Copanlisib

Table 69: Safety of Copanlisib

Table 70: Copanlisib SWOT Analysis, 2015

Table 71: Product Profile – Duvelisib

Table 72: Efficacy of Duvelisib

Table 73: Safety of Duvelisib

Table 74: Duvelisib SWOT Analysis, 2015

Table 75: Product Profile – Gazyva

Table 76: Efficacy of Gazyva in Indolent NHL

Table 77: Efficacy of Gazyva in DLBCL

Table 78: Safety of Gazyva

Table 79: Safety of Gazyva in DLBCL

Table 80: Gazyva SWOT Analysis, 2015

Table 81: Product Profile – Opdivo

Table 82: Efficacy of Opdivo

Table 83: Safety of Opdivo

Table 84: Opdivo SWOT Analysis, 2015

Table 85: Early-Stage Pipeline Products in Non-Hodgkin’s Lymphoma

Table 86: Clinical Benchmarking of Key Marketed and Pipeline Drugs – Indolent NHL, First-Line Therapies, 2015

Table 87: Clinical Benchmarking of Key Marketed and Pipeline Drugs – Indolent NHL, Relapsed/Refractory Therapies, 2015

Table 88: Clinical Benchmarking of Key Marketed and Pipeline Drugs – Indolent NHL, Consolidation/Maintenance Therapies, 2015

Table 89: Clinical Benchmarking of Key Marketed and Pipeline Drugs – Aggressive NHL, First-Line Therapies, 2015

Table 90: Clinical Benchmarking of Key Marketed and Pipeline Drugs – Aggressive NHL, Relapsed/Refractory Therapies, 2015

Table 91: Clinical Benchmarking of Key Marketed and Pipeline Drugs – Aggressive NHL, Consolidation/Maintenance Therapies, 2015

Table 92: Commercial Benchmarking of Key Marketed and Pipeline Drugs – NHL, 2015

Table 93: Commercial Benchmarking of Key Marketed and Pipeline Drugs – NHL, 2015 (continued from Table 93)

Table 94: Top-Line Sales Forecasts ($bn) for NHL, 2014–2024

Table 95: Key Events Impacting Sales for NHL in the 7MM, 2014–2024

Table 96: NHL Market in the US and 5EU – Drivers and Barriers, 2015

Table 97: NHL Patient Population Segmentations in the 7MM – Secondary Sources

Table 98: Patient Populations Targeted by NHL Marketed and Pipeline Drug Developers

Table 99: NHL Marketed and Pipeline Products Broken Down by Therapeutic Class

Table 100: Key Branded Drug Key Launch Dates and Patent Expiries for NHL in the 7MM

Table 101: Key Generic and Biosimilar Entry Dates for NHL in the 7MM

Table 102: High-Prescribing Physicians Surveyed by Country